Quick Answer
Pyxis Oncology, Inc. reported Total Assets of $91.52 million for the year ending 2025.
- Pyxis Oncology, Inc. showed a decrease of -41.8% in Total Assets from 2024 to 2025.
- This data is from Pyxis Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $139.49 million | Q1 2022: $252.70 million | Q2 2022: $242.56 million | Q3 2022: $223.90 million | Q1 2023: $182.80 million | Q2 2023: $175.23 million | Q3 2023: $186.69 million | Q1 2024: $220.22 million | Q2 2024: $208.39 million | Q3 2024: $195.31 million | Q1 2025: $135.87 million | Q2 2025: $123.22 million | Q3 2025: $105.60 million.
- Over the full 6 years of available data (2020 to 2025), Pyxis Oncology, Inc.'s Total Assets has grown by 801.6%.
- Historical annual values: Fiscal year 2025: $91.52 million | Fiscal year 2024: $157.18 million | Fiscal year 2023: $173.73 million | Fiscal year 2022: $211.38 million | Fiscal year 2021: $280.02 million | Fiscal year 2020: $10.15 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: